Adipocytes as a vehicle for exvivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases

Journal of Diabetes Investigation

Volumn 2, Issue 5, 2011, Pages 333-340

  Kuroda, Masayuki ^a   Bujo, Hideaki ^b   Aso, Masayuki ^d   Saito, Yasushi ^c  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d CellGenTech Inc   (Japan)

Author keywords

Adipocyte; Gene therapy; Metabolic disease

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; BETA GLUCURONIDASE; CILIARY NEUROTROPHIC FACTOR; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; IDURONATE 2 SULFATASE; LENTIVIRUS VECTOR; LEVO IDURONIDASE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NAKED DNA; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RETROVIRUS VECTOR; TISSUE SCAFFOLD;

ADENOSINE DEAMINASE DEFICIENCY; ADIPOCYTE; ADIPOSE TISSUE; ALPHA 1 ANTITRYPSIN DEFICIENCY; BONE MARROW TRANSPLANTATION; CELL BASED GENE THERAPY; CELL MEMBRANE POTENTIAL; CELL TRANSPLANTATION; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EX VIVO GENE TRANSFER; FAMILIAL HYPERCHOLESTEROLEMIA; GAUCHER DISEASE; GENETIC TRANSDUCTION; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUNTER SYNDROME; HUNTINGTON CHOREA; HURLER SYNDROME; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE DEFICIENCY; IN VIVO STUDY; INTRAHEPATIC DRUG ADMINISTRATION; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; METABOLIC SYNDROME X; MONOGENIC DISORDER; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN DEFICIENCY; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; X LINKED CHRONIC GRANULOMATOUS DISEASE; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 80053984179     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00133.x     Document Type: Review

References (82)

1. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.
2. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008; 15: 711-715.
3. Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111: 4431-4444.
4. Qasim W, Gaspar HB, Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther 2009; 16: 1285-1291.
5. Reiser J, Zhang XY, Hemenway CS, et al. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005; 5: 1571-1584.
6. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
7. Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998; 91: 30-36.
8. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
9. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
10. Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010; 115: 783-791.
11. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
12. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
13. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
14. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007; 117: 1456-1465.
15. Pike-Overzet K, van der Burg M, Wagemaker G, et al. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007; 15: 1910-1916.
16. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
17. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-341.
18. Nguyen TH, Mainot S, Lainas P, et al. Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 2009; 9: 136-149.
19. Vaessen SF, Twisk J, Kastelein JJ, et al. Gene therapy in disorders of lipoprotein metabolism. Curr Gene Ther 2007; 7: 35-47.
20. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
21. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
22. Chuah MK, Collen D, Vandendriessche T. Preclinical and clinical gene therapy for haemophilia. Haemophilia 2004; 10(Suppl. 4): 119-125.
23. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140: 479-487.
24. Petrus I, Chuah M, VandenDriessche T. Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med 2010; 12: 797-809.
25. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
26. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716.
27. Billings E Jr, May JW Jr. Historical review and present status of free fat graft autotransplantation in plastic and reconstructive surgery. Plast Reconstr Surg 1989; 83: 368-381.
28. Patrick CW Jr. Adipose tissue engineering: the future of breast and soft tissue reconstruction following tumor resection. Semin Surg Oncol 2000; 19: 302-311.
29. Patrick CW Jr. Tissue engineering strategies for adipose tissue repair. Anat Rec 2001; 263: 361-366.
30. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
31. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-365.
32. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339.
33. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-1856.
34. Casteilla L, Cousin B, Planat-Benard V, et al. Virus-based gene transfer approaches and adipose tissue biology. Curr Gene Ther 2008; 8: 79-87.
35. Ito M, Bujo H, Takahashi K, et al. Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia 2005; 48: 1614-1620.
36. Kitagawa Y, Bujo H, Takahashi K, et al. Impaired glucose tolerance is accompanied by decreased insulin sensitivity in tissues of mice implanted with cells that overexpress resistin. Diabetologia 2004; 47: 1847-1853.
37. Kubota Y, Unoki H, Bujo H, et al. Low-dose GH supplementation reduces the TLR2 and TNF-alpha expressions in visceral fat. Biochem Biophys Res Commun 2008; 368: 81-87.
38. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783-787.
39. Shimizu T, Ishikawa T, Sugihara E, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29: 5687-5699.
40. Barnes CP, Sell SA, Boland ED, et al. Nanofiber technology: designing the next generation of tissue engineering scaffolds. Adv Drug Deliv Rev 2007; 59: 1413-1433.
41. Dawson E, Mapili G, Erickson K, et al. Biomaterials for stem cell differentiation. Adv Drug Deliv Rev 2008; 60: 215-228.
42. Aoyagi Y, Kuroda M, Asada S, et al. Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice. Exp Mol Med 2011; 43: 161-167.
43. Kimura Y, Ozeki M, Inamoto T, et al. Adipose tissue engineering based on human preadipocytes combined with gelatin microspheres containing basic fibroblast growth factor. Biomaterials 2003; 24: 2513-2521.
44. Kuramochi D, Unoki H, Bujo H, et al. Matrix metalloproteinase 2 improves the transplanted adipocyte survival in mice. Eur J Clin Invest 2008; 38: 752-759.
45. Matsumoto F, Bujo H, Kuramochi D, et al. Effects of nutrition on the cell survival and gene expression of transplanted fat tissues in mice. Biochem Biophys Res Commun 2002; 295: 630-635.
46. Ning H, Liu G, Lin G, et al. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. J Sex Med 2009; 6: 967-979.
47. Shibasaki M, Takahashi K, Itou T, et al. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun 2003; 309: 419-424.
48. Shibasaki M, Takahashi K, Itou T, et al. Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia 2002; 45: 518-526.
49. Torio-Padron N, Borges J, Momeni A, et al. Implantation of VEGF transfected preadipocytes improves vascularization of fibrin implants on the cylinder chorioallantoic membrane (CAM) model. Minim Invasive Ther Allied Technol 2007; 16: 155-162.
50. Yamaguchi M, Matsumoto F, Bujo H, et al. Revascularization determines volume retention and gene expression by fat grafts in mice. Exp Biol Med (Maywood) 2005; 230: 742-748.
51. Fraser JK, Wulur I, Alfonso Z, et al. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006; 24: 150-154.
52. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260.
53. Gomillion CT, Burg KJ. Stem cells and adipose tissue engineering. Biomaterials 2006; 27: 6052-6063.
54. Sugihara H, Yonemitsu N, Miyabara S, et al. Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. Differentiation 1986; 31: 42-49.
55. Kuroda M, Aoyagi Y, Asada S, et al. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. Open Gene Ther J 2011; 4: 1-10.
56. Asada S, Kuroda M, Aoyagi Y, et al. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. Am J Physiol Cell Physiol 2011; (in press). doi:.
57. Santamarina-Fojo S, Hoeg JM, Assman G, et al. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Volkman BF (eds). The Metabolic and Molecular Bases of Inherited Disease, 8th Edn. McGraw-Hill Inc, New York, 2001; 2817-2833.
58. The Human Gene Mutation Database at Institute of Medical Genetics in Cardiff (HGMD).
59. Asada S, Kuroda M, Aoyagi Y, et al. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Mol Genet Metab 2011; 102: 229-231.
60. Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000; 11: 1023-1032.
61. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93-128.
62. Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther 2003; 10: 95-99.
63. Bellon G, Michel-Calemard L, Thouvenot D, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997; 8: 15-25.
64. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079-1088.
65. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007; 18: 726-732.
66. Wagner JA, Nepomuceno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13: 1349-1359.
67. Dunbar C, Kohn D. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 1996; 7: 231-253.
68. Dunbar CE, Kohn DB, Schiffmann R, et al. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther 1998; 9: 2629-2640.
69. Bachoud-Levi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000; 11: 1723-1729.
70. Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15: 968-975.
71. Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006; 26: 1236-1245.
72. Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 2005; 16: 1276-1286.
73. Baxter MA, Wynn RF, Deakin JA, et al. Retrovirally mediated correction of bone marrow-derived mesenchymal stem cells from patients with mucopolysaccharidosis type I. Blood 2002; 99: 1857-1859.
74. Fairbairn LJ, Lashford LS, Spooncer E, et al. Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow. Proc Natl Acad Sci USA 1996; 93: 2025-2030.
75. Stroncek DF, Hubel A, Shankar RA, et al. Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome. Transfusion 1999; 39: 343-350.
76. Hennig AK, Levy B, Ogilvie JM, et al. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 2003; 23: 3302-3307.
77. Hofling AA, Devine S, Vogler C, et al. Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther 2004; 9: 856-865.
78. Hofling AA, Sands MS, Lublin DM, et al. Collection of a mobilized peripheral blood apheresis product from a patient with mucopolysaccharidosis type VII and subsequent CD34+ cell isolation. J Clin Apher 2004; 19: 151-153.
79. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-175.
80. Fraites TJ Jr, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571-578.
81. Mah C, Cresawn KO, Fraites TJ Jr, et al. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 2005; 12: 1405-1409.
82. Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther 2007; 15: 501-507.